Print page
Email page
Download PDF
« Previous Release | Next Release »
MOUNTAIN VIEW, Calif., May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will present three posters on its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program and one poster on its MAP0005 formoterol-budesonide combination asthma therapy program at ATS 2009, the International Conference of the American Thoracic Society, in San Diego on May 18, 2009.
The four posters can be viewed on Monday, May 18 between 8:15 a.m. and 4:00 p.m. Pacific Time. The presentations are titled:
-- "Unit Dose Budesonide (UDB): A New Submicron Dispersion of
Nebulizable Budesonide Studied in 360 Children 12 Months to 8 Years Old
with Mild to Moderate Persistent Asthma--The CASTLE I Study"
-- "A Novel Budesonide Formulation for Nebulization Significantly
Improves the Amount of Drug Emitted over One Minute in a Simulated
Pediatric Tidal Breathing Model"
-- "A Novel Aqueous Dispersion of Budesonide Significantly Improves
the Aerodynamic Particle Sizing Distribution of Budesonide from Various
Jet Nebulizers Compared to a Marketed Budesonide Suspension"
-- "Comparative Pharmacodynamics and Pharmacokinetics of MAP0005
(Formoterol-Budesonide Combination Particles Delivered via the Tempo(R)
Inhaler) in Mild to Moderate Asthmatics"
Copies of the posters will be available under the Publications tab of the MAP Pharmaceuticals website on Monday, May 18.
About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
Contact:
MAP Pharmaceuticals, Inc.
Lisa Borland
Media Contact
650-386-3122
lborland@mappharma.com
SOURCE MAP Pharmaceuticals, Inc.
http://www.mappharma.com
Copyright (C) 2009 PR Newswire. All rights reserved